Entecavir with or without interferon for children 3-6 with hepatitis B
Treatments studied
Part of Digestive system, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests whether adding a short course of interferon to standard antiviral medicine (entecavir) helps younger children with chronic hepatitis B whose immune system has not yet started fighting the virus. It aims to see if this combination can lead to a functional cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 and 6 years old (older than 3 but younger than 7).
- Your child must have chronic hepatitis B (a long-term liver infection).
- Your child's blood tests must show a high amount of hepatitis B virus (HBV DNA over 10 million IU/mL) and specific markers (HBeAg positive).
- Your child must have normal liver ultrasound and normal liver enzymes (ALT below 40 U/L).
- Your child must not have had any previous treatment for hepatitis B.
- Your child must not have other serious liver diseases, certain other infections, or take medicines that could affect the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for young children (ages 3–6) with active chronic hepatitis B: entecavir alone versus entecavir plus a short course of pegylated interferon. The goal is to see if adding interferon helps control the infection better.
This study looks at how well antiviral medicines work for children with long-term hepatitis B. It may help doctors find the best way to treat or stop treatment for kids who have had the virus for a while.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.